Paper36951997
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
Kayki-Mutlu G and 3 others. Naunyn Schmiedebergs Arch Pharmacol, 2023. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Papers, record 36951997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36951997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Biological Products | Major topic |
| United States | |
| Humans | |
| United States Food and Drug Administration | |
| Pandemics | |
| Pharmaceutical Preparations | |
| Drug Approval |
Source PubMed
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25904506 | IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25904506 | PubMed |
| 2 | 34495425 | Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. | Jpn J Ophthalmol | 2021 | https://conductscience.org/library/papers/34495425 | PubMed |
| 3 | 34529832 | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. | Br J Pharmacol | 2021 | https://conductscience.org/library/papers/34529832 | PubMed |
| 4 | 35417638 | Mitapivat versus Placebo for Pyruvate Kinase Deficiency. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35417638 | PubMed |
| 5 | 35652823 | Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. | Amyloid | 2022 | https://conductscience.org/library/papers/35652823 | PubMed |
| 6 | 35820547 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. | J Am Acad Dermatol | 2023 | https://conductscience.org/library/papers/35820547 | PubMed |
| 7 | 35736599 | New Drug for Metastatic Castration-Resistant Prostate Cancer. | Am J Nurs | 2022 | https://conductscience.org/library/papers/35736599 | PubMed |
| 8 | 34936739 | Trial of Spesolimab for Generalized Pustular Psoriasis. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34936739 | PubMed |
| 9 | 35946351 | Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? | Immunotherapy | 2022 | https://conductscience.org/library/papers/35946351 | PubMed |
| 10 | 31791824 | DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). | J Am Acad Dermatol | 2020 | https://conductscience.org/library/papers/31791824 | PubMed |
| 11 | 33761207 | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33761207 | PubMed |
| 12 | 36418672 | Spesolimab: First Approval. | Drugs | 2022 | https://conductscience.org/library/papers/36418672 | PubMed |
| 13 | 35785754 | Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. | Cancer Treat Rev | 2022 | https://conductscience.org/library/papers/35785754 | PubMed |
| 14 | 32818963 | A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32818963 | PubMed |
| 15 | 36387582 | A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. | Lung Cancer (Auckl) | 2022 | https://conductscience.org/library/papers/36387582 | PubMed |
| 16 | 35803286 | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/35803286 | PubMed |
| 17 | 31609882 | DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). | Plast Reconstr Surg | 2020 | https://conductscience.org/library/papers/31609882 | PubMed |
| 18 | 35679950 | Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. | Gastroenterology | 2022 | https://conductscience.org/library/papers/35679950 | PubMed |
| 19 | 32687266 | A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study. | Cancer Med | 2020 | https://conductscience.org/library/papers/32687266 | PubMed |
| 20 | 27042127 | Tremelimumab: research and clinical development. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27042127 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41807809 | A year in pharmacology: new drugs approved by the US food and drug administration in 2025. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41807809 | PubMed |
| 41196339 | Do GPCRs constitute the target of 30% of newly approved drugs in Germany? | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41196339 | PubMed |
| 40608116 | Comparison of drug approvals of the FDA and EMA between 2013 and 2023. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/40608116 | PubMed |
| 40163152 | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40163152 | PubMed |
| 39177747 | The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model. | Handb Exp Pharmacol | 2024 | https://conductscience.org/library/papers/39177747 | PubMed |
| 38530400 | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/38530400 | PubMed |
| 38371570 | Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage. | Indian J Dermatol | 2023 | https://conductscience.org/library/papers/38371570 | PubMed |
Genes31
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36951997
GET https://conductscience.org/api/papers/v1/36951997/references?page=2